Published rivaroxaban dosing strategy in Einstein Jr and UNIVERSE clinical trials
| Einstein Jr phase 3 (VTE treatment) Body weight–adjusted rivaroxaban regimens in a 20-mg equivalent dose . | UNIVERSE phase 3 (post-Fontan thromboprophylaxis) Body weight–adjusted rivaroxaban regimens in a 10-mg equivalent dose (mg or mL∗) . | ||||
|---|---|---|---|---|---|
| Body weight . | Dose . | Total . | Body weight . | Dose . | Total . |
| 2.6 to <3 kg | 0.8 mg per dose TID | 2.4 mg | 7 to <8 kg | 1.1 mg per dose BID | 2.2 mg |
| 3 to <4 kg | 0.9 mg per dose TID | 2.7 mg | 8 to <10 kg | 1.6 mg per dose BID | 3.2 mg |
| 4 to <5 kg | 1.4 mg per dose TID | 4.2 mg | 10 to <12 kg | 1.7 mg per dose BID | 3.4 mg |
| 5 to <7 kg | 1.6 mg per dose TID | 4.8 mg | 12 to <20 kg | 2 mg per dose BID | 4.0 mg |
| 7 to <8 kg | 1.8 mg per dose TID | 5.4 mg | 20 to <30 kg | 2.5 mg per dose BID | 5.0 mg |
| 8 to <9 kg | 2.4 mg per dose TID | 7.2 mg | |||
| 9 to <10 kg | 2.8 mg per dose TID | 8.4 mg | |||
| 10 to <12 kg | 3 mg per dose TID | 9 mg | |||
| 12 to <30 kg | 5 mg per dose BID | 10 mg | |||
| 30 to <50 kg | 15 mg per dose OD | 15 mg | |||
| ≥50 kg | 20 mg per dose OD | 20 mg | |||
| Einstein Jr phase 3 (VTE treatment) Body weight–adjusted rivaroxaban regimens in a 20-mg equivalent dose . | UNIVERSE phase 3 (post-Fontan thromboprophylaxis) Body weight–adjusted rivaroxaban regimens in a 10-mg equivalent dose (mg or mL∗) . | ||||
|---|---|---|---|---|---|
| Body weight . | Dose . | Total . | Body weight . | Dose . | Total . |
| 2.6 to <3 kg | 0.8 mg per dose TID | 2.4 mg | 7 to <8 kg | 1.1 mg per dose BID | 2.2 mg |
| 3 to <4 kg | 0.9 mg per dose TID | 2.7 mg | 8 to <10 kg | 1.6 mg per dose BID | 3.2 mg |
| 4 to <5 kg | 1.4 mg per dose TID | 4.2 mg | 10 to <12 kg | 1.7 mg per dose BID | 3.4 mg |
| 5 to <7 kg | 1.6 mg per dose TID | 4.8 mg | 12 to <20 kg | 2 mg per dose BID | 4.0 mg |
| 7 to <8 kg | 1.8 mg per dose TID | 5.4 mg | 20 to <30 kg | 2.5 mg per dose BID | 5.0 mg |
| 8 to <9 kg | 2.4 mg per dose TID | 7.2 mg | |||
| 9 to <10 kg | 2.8 mg per dose TID | 8.4 mg | |||
| 10 to <12 kg | 3 mg per dose TID | 9 mg | |||
| 12 to <30 kg | 5 mg per dose BID | 10 mg | |||
| 30 to <50 kg | 15 mg per dose OD | 15 mg | |||
| ≥50 kg | 20 mg per dose OD | 20 mg | |||
Reprinted from McCrindle et al17 (© 2021 by the authors; published on behalf of the American Heart Association, Inc, by Wiley Blackwell), with permission from Wiley Blackwell, and from Male et al16 with permission from Elsevier.
BID, twice daily; OD, once daily; TID, 3 times daily.
Oral suspension 0.1% (1 mg/mL).